TVTX

Travere Therapeutics Inc.

Price

$65.96

return (12m)

274.13%

p/e

-131.71

p/bv

233.45

DIVIDEND YIELD

0.00%

TVTX price

Travere Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TVTX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

17.51%

3 months

47.43%

1 year

274.13%

2 years

632.89%

5 years

212.31%

10 years

286.18%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals TVTX

Valuation

P/E

-131.71

Sector -4.38

Industry -4.38

P/BV

233.45

Sector 2.02

Industry 2.02

P/Revenue (PSR)

9.68

Sector -4.40

Industry -4.40

EV/EBITDA

-203.90

Sector -263.09

Industry -263.09

EV/EBIT

-177.60

Sector -702.90

Industry -702.90

P/EBITDA

990.34

Sector -4.39

Industry -4.39

P/EBIT

-99.39

Sector -4.73

Industry -4.73

P/Total Assets

7.16

Sector 1.49

Industry 1.49

P/Net Current Assets

-35.84

Sector -11.70

Industry -11.70

P/Working Capital

12.36

Sector -3.19

Industry -3.19

EPS

-0.47

Sector -2.14

Industry -2.14

BVPS

0.26

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

93.21%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-16.88%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-19.38%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-6.84%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-7.35%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.21

Sector 0.03

Industry 0.03

Profitability

ROE

-177.24%

Sector -65.14%

Industry -65.14%

ROA

-5.44%

Sector -65.53%

Industry -65.53%

ROIC

7.62%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.05

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-3.97

Sector -6.07

Industry -6.07

Net Debt / EBIT

-3.46

Sector -8.26

Industry -8.26

Net Debt / Equity

4.63

Sector -1.07

Industry -1.07

Gross Debt / Equity

24.58

Sector -0.05

Industry -0.05

Equity/Assets

0.03

Sector 0.41

Industry 0.41

Liabilities/Assets

0.97

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

35.01%

Sector -

Industry -

5Y Earnings CAGR

-24.75%

Sector -

Industry -

Fundamentals TVTX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TVTX Travere Therapeutics Inc.	$65.96	251.41%	0.00%	-131.71	233.45	-177.24%	-7.35%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TVTX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Travere Therapeutics

Travere Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

15 years

Founded: 2011

2003

Time since IPO - 23 years

262

Employees

Travere Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $5.72 billion, with shareholders equity totaling $24.52 million.

The company employs approximately 262 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Travere Therapeutics Inc. reported $591.33 million in revenue, generating net income of $-43.46 million.

Key financial metrics include a P/E ratio of -131.71, a price-to-book (P/B) ratio of 233.45, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TVTX.

Market cap

$5.72 billion

Net worth

$24.52 million

$24,520,000.00

Assets

$799.36 million

$799,360,000.00

Total Shares Outstanding

93.00 million

93,000,000

Average Daily Trading Volume

$1.90 million

$1,896,656.80

Sector

Health Care

Industry

Biotechnology

TVTX

TVTX revenue and profits

Financial Results TVTX

DRAG THE FRAME TO SEE MORE DATA

TVTX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Travere Therapeutics (TVTX) today?

A cotação de Travere Therapeutics (TVTX) hoje está em US$ 65.96, com uma variação de 274.13% em relação ao último ano. A cotação de Travere Therapeutics (TVTX) iniciou o ano negociando na casa dos US$ 38.21 e hoje está em US$ 65.96. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Travere Therapeutics (TVTX) e dados de ações do Ibovespa e mercados internacionais.

Quando Travere Therapeutics (TVTX) paga dividendos?

Travere Therapeutics (TVTX) não distribuiu dividendos no último ano.

Is Travere Therapeutics (TVTX) a good investment?

Atualmente, Travere Therapeutics (TVTX) está cotada a US$ 65.96, com um P/L de -131.71, representando um desvio de -5,597% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 274.13 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 274.13%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Travere Therapeutics (TVTX) stock?

Investir em ações de Travere Therapeutics (TVTX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Travere Therapeutics (TVTX) yield today?

A rentabilidade de Travere Therapeutics (TVTX) foi de 17.51% no último mês, 274.13% no último ano e 212.31% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Travere Therapeutics (TVTX) hoje, o investimento total seria de US$ 6,596.00, com base na cotação atual de US$ 65.96.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 24,677.61
Em 5 anos: US$ 20,599.97
Em 10 anos: US$ 25,472.43

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

TVTX

Travere Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TVTX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING TVTX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Travere Therapeutics

Travere Therapeutics Inc.

United States

15 years

2003

262

PROFIT X PRICE TVTX

Financial Results TVTX

TVTX cash flow

Asset, Revenue and Profit Growth - TVTX

TVTX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions